Stock listing
LIMN Stock Price, News, Filings & Events — Liminatus Pharma, Inc.
Selected listing: LIMN · NASDAQ · USD · US
This page tracks Liminatus Pharma, Inc.'s LIMN:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following LIMN:NASDAQ. LIMN:NASDAQ is the stock-level entry point for investors researching Liminatus Pharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Liminatus Pharma, Inc. is a public company traded under the ticker LIMN in the American market. The company has a market capitalization of approximately $7.45 million. Liminatus Pharma focuses on developing innovative pharmaceutical solutions.
- Ticker
- LIMN:NASDAQ
- Asset type
- Stock
- Market cap
- $4.7M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Liminatus Pharma, Inc. LIMN:NASDAQ stock context
This page tracks Liminatus Pharma, Inc.'s LIMN:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following LIMN:NASDAQ. LIMN:NASDAQ is the stock-level entry point for investors researching Liminatus Pharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Liminatus Pharma, Inc. is a public company traded under the ticker LIMN in the American market. The company has a market capitalization of approximately $7.45 million. Liminatus Pharma focuses on developing innovative pharmaceutical solutions.
Latest news from Liminatus Pharma, Inc.
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T t...
August 24, 2026
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
August 18, 2026
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
August 13, 2026
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
June 3, 2026
Liminatus Pharma Announces Nasdaq Delisting Notification
May 21, 2026
Research Liminatus Pharma, Inc.
Liminatus Pharma, Inc. investor report
Review AI stock analysis and investor report context for LIMN:NASDAQ.
Liminatus Pharma, Inc. company profile
View the public company page for Liminatus Pharma, Inc. on 6ix.
Liminatus Pharma, Inc. news
Read company news and market updates connected to Liminatus Pharma, Inc..
Liminatus Pharma, Inc. investor events
Find investor webinars, events, and replay context for Liminatus Pharma, Inc..